The widely used diabetes drug gliclazide has been linked to an increased risk of hypoglycaemia and cardiac death, Australian researchers have warned. In a study of 30 well-controlled patients with type 2 diabetes treated with the sulfonylurea some 30% of patients experienced clinically significant hypoglycaemia over a 48-hour period of continuous blood glucose monitoring. Worryingly, ...
Gliclazide not exempt from sulfonylurea-related hypoglycaemia
23 Jun 2017